Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

BACKGROUND: Children account for a substantial proportion of cases and deaths from Ebola virus disease. We aimed to assess the safety and immunogenicity of a two-dose heterologous vaccine regimen, comprising the adenovirus type 26 vector-based vaccine encoding the Ebola virus glycoprotein (Ad26.ZEBO...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Infect Dis
Main Authors: Afolabi, Muhammed O, Ishola, David, Manno, Daniela, Keshinro, Babajide, Bockstal, Viki, Rogers, Baimba, Owusu-Kyei, Kwabena, Serry-Bangura, Alimamy, Swaray, Ibrahim, Lowe, Brett, Kowuor, Dickens, Baiden, Frank, Mooney, Thomas, Smout, Elizabeth, Köhn, Brian, Otieno, Godfrey T, Jusu, Morrison, Foster, Julie, Samai, Mohamed, Deen, Gibrilla Fadlu, Larson, Heidi, Lees, Shelley, Goldstein, Neil, Gallagher, Katherine E, Gaddah, Auguste, Heerwegh, Dirk, Callendret, Benoit, Luhn, Kerstin, Robinson, Cynthia, Greenwood, Brian, Leyssen, Maarten, Douoguih, Macaya, Leigh, Bailah, Watson-Jones, Deborah
Formato: Artigo
Idioma:Inglês
Publicado em: 2022
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7613317/
https://ncbi.nlm.nih.gov/pubmed/34529962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(21)00128-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados